Literature DB >> 8590623

Alcoholic hypogonadism: hormonal response to clomiphene.

A Martínez-Riera1, F Santolaria-Fernández, E González Reimers, A Milena, J L Gómez-Sirvent, F Rodríguez-Moreno, I González-Martín, E Rodríguez-Rodríguez.   

Abstract

To investigate the androgen, weak androgen, estrogen, and gonadotrophin response to clomiphene in alcoholics, we determined in 63 male patients (25 with and 38 without liver cirrhosis) serum testosterone, sexual hormone binding protein (SHBG), dehidroepiandrosterone, androstenedione, LH, FSH, prolactin, and estradiol levels, on the first and the sixth day after admission, and after a course of 8 days of clomiphene 200 mg/day. The same test was performed on 15 healthy volunteers. Cirrhotic patients showed decreased basal testosterone levels and a loss of the circadian rhythm with recovery after clomiphene. Although basal testosterone levels in noncirrhotic alcoholics did not differ from those of the controls, there was a significant improvement after withdrawal. SHBG levels were higher in both groups of alcoholics than in controls, pointing to a worse degree of hypogonadism, because only the free hormone is active. Before the clomiphene test, serum LH and FSH levels were nonsignificantly higher in both groups of alcoholics than in the control group. After clomiphene both LH and FSH increased. Androstenedione and estradiol showed a (parallelism) similar behavior in alcoholic and in cirrhotic groups, showing in both cases higher levels than in the control group, and an increase after clomiphene, perhaps reflecting peripheral conversion of androgens to estrogens. Because clomiphene has no effect on the adrenal cortex, the increase of androstenedione after clomiphene points to its testicular origin (directly or after testosterone conversion) and not to an adrenal one. The highest serum estradiol levels were observed in cirrhotics with ascites or gynecomastia. We have not found any relation between serum hormone levels and alcohol intake nor with nutritional status.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590623     DOI: 10.1016/0741-8329(95)02006-3

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  7 in total

Review 1.  Effects of alcohol on the endocrine system.

Authors:  Nadia Rachdaoui; Dipak K Sarkar
Journal:  Endocrinol Metab Clin North Am       Date:  2013-09       Impact factor: 4.741

2.  Physiological levels of estradiol correlate with lipid / lipoprotein profiles in healthy men.

Authors:  N Shono; Y Higaki; M Mori; M Nishizumi
Journal:  Environ Health Prev Med       Date:  1999-07       Impact factor: 3.674

3.  Ethanol induces conditioned social preference in male mice.

Authors:  Kelly Kent; Kaelan Butler; Ruth I Wood
Journal:  Alcohol Clin Exp Res       Date:  2014-01-24       Impact factor: 3.455

4.  Increase of hypophyseal hormone levels in male head and neck cancer patients.

Authors:  Eva Remenár; Irén Számel; Barna Budai; Borbála Vincze; István Gaudi; Sarolta Gundy; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

5.  Quantification of ten neuroactive steroids in plasma in Withdrawal Seizure-Prone and -Resistant mice during chronic ethanol withdrawal.

Authors:  Christopher Snelling; Michelle A Tanchuck-Nipper; Matthew M Ford; Jeremiah P Jensen; Debra K Cozzoli; Marcia J Ramaker; Melinda Helms; John C Crabbe; David J Rossi; Deborah A Finn
Journal:  Psychopharmacology (Berl)       Date:  2014-05-29       Impact factor: 4.530

Review 6.  Pathophysiology of the Effects of Alcohol Abuse on the Endocrine System.

Authors:  Nadia Rachdaoui; Dipak K Sarkar
Journal:  Alcohol Res       Date:  2017

7.  Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial.

Authors:  Talles Bazeia Lima; Lívia Alves Amaral Santos; Hélio Rubens de Carvalho Nunes; Giovanni Faria Silva; Carlos Antonio Caramori; Xingshun Qi; Fernando Gomes Romeiro
Journal:  Sci Rep       Date:  2019-12-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.